Alnylam Pharmaceuticals
ALNY
#627
Rank
ยฃ25.49 B
Marketcap
ยฃ197.64
Share price
0.40%
Change (1 day)
49.60%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of September 2024 : ยฃ1.03 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is ยฃ1.03 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2023-12-31ยฃ1.02 B-6.11%
2022-12-31ยฃ1.09 B47.66%
2021-12-31ยฃ0.73 B93.28%
2020-12-31ยฃ0.38 B65.03%
2019-12-31ยฃ0.23 B880.35%
2018-12-31ยฃ23.63 M6.47%
2017-12-31ยฃ22.19 M-81.74%
2016-12-31ยฃ0.12 B
2007-12-31ยฃ3.4 M-27.07%
2006-12-31ยฃ4.66 M8.77%
2005-12-31ยฃ4.28 M14.33%
2004-12-31ยฃ3.75 M260.93%
2003-12-31ยฃ1.03 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
ยฃ93.43 M-90.93%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ2.13 B 107.71%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ1.10 B 7.35%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.21 B-79.30%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.53 M-99.95%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ25.44 B 2,370.29%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
ยฃ20.14 B 1,855.76%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ15.25 B 1,380.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel